Ye of little faith, and that has always been apparent. This
Ye of little faith, and that has always been apparent. This much we know about you.
I do feel we have a pathway to success in many directions. You can call it what you want. But Covid will be our first EUA and quite possibly our first full approval. It may not be here. But other countries don’t have our political bearing on their approval process. I am betting U.K. is our first EUA or PIM as they call it. Probably our first full Approval also.
One thing I have learned. It’s hard for a little company to rub elbows with big companies that have tons of money to throw out there to slow everyone else down to a crawl. Maybe our new strategy of having our doctor visiting every open trial site will show that money isn’t everything and letting our little molecule compete is well deserving and life changing if they actually use Leronlimab. I see this pathway well lit now and a faster trial because of this extra effort of our doctor beating down the door of trial hospitals.
I see a better pathway forward for our cancer trials with extra testing for more markers and for someone to help us get our BTD there. I just feel that Dr. Mahboob Rahman will not disappoint us. It is the single best thing we have done as a company this year is to hire someone to bring us the experience of completing a BLA or complete the filing of a indication that gets approval. Cancer is a great path for Leronlimab. Today we had Dr. Patterson’s tweet shows you his opinion is still very high of Leronlimab for cancer among other indications too.
I also like very much the starting of other block buster potential indications like NASH and Alzheimer’s and starting of protocols for Long Haulers and maybe Moderate Covid patients by end of 2021.
So you can be negative and see a slow process somehow seem slower than we all like or want. The real bone you can chew on is that we aren’t a one show drug. We will have indications get approval if we can just get over the hump and get that first approval. I believe a Covid approval is soon. I believe our cancer trials will be proven to extend lives. I believe we are doing the right thing to start the trials as soon as possible for other indications that are life saving and possibly BTD or label extensions instead of approvals. It’s just getting that first one that’s taking forever. But we are closer and closer all the time.
We are early and under budget so we have a great path already. Getting our first approval will be not that far in the future. That’s the reason(s) I have faith. We as a company are not a one pony show. We have options and directions to achieve our end goals. It’s hard for me to get discouraged when everything seems to be coming together. With trial results we think we have and never taking a step backwards of safety or efficacy. It’s not IF... it’s when!
I haven’t sold one share in the past year. I watch and I watch. It went up and it went down. I never stopped believing. Dr. Patterson’s Ted Talkx locked me into... it’s just a matter of time. Time is something I have. So I like you... Wait... but time is narrowing and it’s much closer than we know.
13
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Wall Street's Latest Drama: BAC's Legal Battle Bank of America, the hulking giant of finance, is neck-deep in a new legal whirlwind. They're slapped with a class action suit alleging securities law violations. Branded under the ticker BAC, Bank of America's actions (or lack thereof) have got shareholders shaking their heads and clenching their wallets. What's Got...
Continue Reading
Pope Leo XIV Embarks on Landmark Latin America Tour While Wall Street rumbles its daily tune, I've got my eyes on a different spectacle: Pope Leo XIV making rounds in South America from November 6 to 17. This isn't your typical news peg. This stretches beyond financial chatter into a spectacle of faith and cultural resonance. No price charts to weave here, just the...
Continue Reading
A Patchwork of Gains and Losses Take a look at Grupo Aeroportuario del Sureste, S.A.B. de C.V. (NYSE: ASR), and you’ll see a mixed bag when it comes to October 2026’s passenger traffic. While some regions like Puerto Rico and Colombia took a step forward, others like Mexico and Costa Rica tripped up, resulting in an overall decline of 0.9% compared to last October....
Continue Reading
Defining the Investor-Entrepreneur Partnership Ah, building a consumer brand is no walk in the park, but what about scaling it? Here's where the rubber really meets the road. Enter Ast? Consumer Partners, a firm that clearly understands that scaling a brand isn't all about throwing cash at it—it’s about precision and the right mix of wisdom, much like a seasoned chef...
Continue Reading
New Alliance in Senior Living: Aegis and Harrison Street Team Up Here's something that caught my eye—two heavy hitters in the senior living sector joining forces for what they're calling a strategic joint venture. Harrison Street, known for its real estate investments with a flair for large-scale projects, has shaken hands with Aegis Living, a name synonymous with...
Continue Reading
Ring the Bell: Dividend Hike from F&G F&G Annuities & Life (NYSE: FG) just raised its dividend, and every investor worth their salt knows that means something. A 4% bump up to $0.26 per common share might not sound like a fanfare, but in the land of finance, it's an indication that this company thinks it's riding a positive wave. It’s like getting a little bonus in your...
Continue Reading
Revolutionizing Apparel Design with AI If you've ever wondered how tech can make an impact on the fashion world, Koozee's latest update provides an eye-opening look. This isn't about following trends—it's about setting them, and Koozee’s making a bold move with its newest platform enhancements. Introducing Freeform Canvas Koozee has launched the Freeform Canvas, a...
Continue Reading
Public Safety on the Line: The Safe Transit Act When city dwellers head to work or school, the last thing they want is a dicey subway ride. Yet, escalating incidents on transit lines are painting a grim picture. From folks getting pushed onto the tracks to outright assault, it's getting hairy out there. The NPA Puts Its Weight Behind Safety The National Police Association...
Continue Reading
Vaccination Confusion: Could Clarity Finally Be Here? Here's the scoop, folks. In the swirling mess of immunization advice, a coalition of top medical societies has thrown a lifeline to clinicians. If you're drowning in conflicting vaccine guidance, this panel's unified stance might just be your life raft. The Coalition Forces of Immunization We have the Vaccine Guidance...
Continue Reading
AiNET's Legal Triumph Shakes Up the IT Sector Well, talk about a courtroom drama. Greenberg Traurig just snagged a big win for AiNET over in Prince George's County, Maryland, and it's a classic reminder that due diligence isn't just a nice-to-have—it's a must. AiNET found itself in the center of a breach of contract brawl with Tech Finance Co., and guess what? The jury...
Continue Reading
Top 5 Most Recently Viewed Articles
Milestone Pharmaceuticals Unveils Plans for Upcoming Investor Event MONTREAL and CHARLOTTE, N.C. — Milestone Pharmaceuticals Inc. (NASDAQ: MIST), a pioneering biopharmaceutical firm dedicated to cardiovascular innovation, is excited to share detailed arrangements for its upcoming investor event. Set to occur in New York, this important gathering will emphasize the...
Continue Reading
Egen Enhances Market Reach with Qarik Acquisition End-to-End Services Enable Organizations to Accelerate their Digital Transformation Journeys Egen, a renowned technology services company, has recently announced its strategic acquisition of Qarik, a successful, multinational Google Cloud Premier Partner. This acquisition marks a significant step forward in Egen's journey,...
Continue Reading
CooperCompanies Delivers Strong Financial Performance SAN RAMON, Calif. -- CooperCompanies (Nasdaq: COO), a prominent leader in the medical device sector, proudly announced its financial results for the fiscal fourth quarter, concluding a successful year ending October 31, 2025. With significant growth demonstrated, the company is setting a sturdy foundation for future...
Continue Reading
DBV Technologies to Showcase Innovations at Major Conference DBV Technologies, a clinical-stage biopharmaceutical company focused on food allergies, is gearing up for its participation in the upcoming Guggenheim 2nd Annual Healthcare Innovation Conference. The event is set to underline the significant advancements in the field of allergy treatment, particularly for food...
Continue Reading
Minesto's Vision for Ocean Energy Technology Minesto has emerged as a leading player in ocean energy technology, pushing the boundaries of innovation and sustainability. The company is committed to harnessing the vast potential of ocean currents to create renewable energy solutions that can contribute significantly to global energy needs. Demonstration of Dragon 4 Tidal...
Continue Reading